Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Ibrance Hopes Dashed In Early-Stage Breast Cancer

Executive Summary

Data from the PENELOPE-B study in high-risk early breast cancer patients show no separation from placebo, compounding the earlier failure of the PALLAS trial in low- and high-risk patients.

You may also be interested in...



Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod

Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.

Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies

Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.

ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS

Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel